The Drug That Cracked the KRAS Code: How Daraxonrasib Is Rewriting the Rules of Pancreatic Cancer

Oncologists do not give standing ovations. The culture of academic medicine runs toward measured skepticism, careful hedging, and the ritual deflation of premature enthusiasm. So when the audience at the 2026 American Society of Clinical Oncology annual meeting in Chicago rose to applaud the presentation of Revolution Medicines' Phase 3 data for daraxonrasib in metastatic pancreatic cancer, it was worth pausing to understand what, exactly, had just happened.

What happened was this: for the first time in the history of clinical oncology, a drug had extended median overall survival past one year in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The number was 13.2 months. The comparator arm, standard cytotoxic chemotherapy, delivered 6.7 months. The hazard ratio was 0.40. The p-value was below 0.0001. In a disease where the five-year survival rate for metastatic patients sits at approximately three percent, and where no prior intervention had ever crossed the one-year median survival threshold in a randomized trial, those numbers are not incremental. They represent a categorical shift in what medicine can offer.

Why Pancreatic Cancer Has Been So Resistant to Progress

To appreciate the significance of the RASolute 302 result, it helps to understand why pancreatic cancer has resisted the targeted therapy revolution that transformed so many other tumor types over the past two decades. The answer lies in a single protein: KRAS. More than 90 percent of pancreatic ductal adenocarcinomas are driven by mutations in the RAS family of proteins, most commonly KRAS G12D, G12V, and G12R. These mutations lock the protein in a constitutively active state, continuously signaling cells to grow and divide regardless of external cues. For decades, KRAS was considered undruggable. The protein's smooth surface offered no obvious binding pocket for small molecules, and its extraordinarily high affinity for GTP made competitive inhibition essentially impossible with conventional chemistry.

The first crack in that wall came with the development of KRAS G12C-specific inhibitors, now marketed as Lumakras and Krazati, which exploit a cysteine residue unique to the G12C variant. Those drugs work in lung cancer, where G12C is the dominant mutation. In pancreatic cancer, G12C is rare. The mutations that drive PDAC, primarily G12D and G12V, lack that cysteine handle, and the G12C inhibitors cannot touch them. The field needed a different approach entirely.

What Daraxonrasib Actually Does

Daraxonrasib is a multi-selective RAS(ON) inhibitor, a class of molecules that works through a fundamentally different mechanism than the G12C inhibitors. Rather than targeting a specific mutant variant, daraxonrasib binds to the active, GTP-bound form of RAS proteins across a broad spectrum of oncogenic mutations, including G12D, G12V, and G12R, as well as wild-type RAS. It suppresses RAS signaling by blocking the interaction between RAS(ON) proteins and their downstream effectors, effectively switching off the signal regardless of which specific mutation is driving it.

That breadth of coverage is precisely what makes the RASolute 302 result so striking. The trial enrolled patients with a wide range of RAS variants, not just a single mutation subtype. The benefit held across the entire intent-to-treat population, not just in a biomarker-selected subset. When a drug works broadly across the mutational heterogeneity of a tumor type as genetically complex as pancreatic cancer, it suggests the mechanism is addressing something fundamental about the disease's biology rather than exploiting a narrow pharmacological opportunity.

The Numbers in Context

The RASolute 302 trial enrolled patients with previously treated metastatic PDAC, a population that has exhausted first-line chemotherapy and faces a median survival measured in months. In that setting, daraxonrasib at 300 mg orally once daily produced a median overall survival of 13.2 months compared to 6.7 months for investigator's choice chemotherapy. Progression-free survival was 7.2 months versus 3.6 months. The objective response rate in the daraxonrasib arm was substantially higher than in the chemotherapy arm. The drug was generally well tolerated, with no new safety signals identified.

Revolution Medicines' chief development officer Alan Sandler noted at ASCO that this was the first time any patients with pancreatic cancer had lived a median of more than a year following a drug intervention in a clinical trial, and that this result was achieved in the second-line setting across the all-comer population. That last qualifier matters. Second-line pancreatic cancer is not a cherry-picked population of good-prognosis patients. It is a group that has already failed one line of treatment and is, by definition, among the most difficult to help.

What Comes Next and What Remains Uncertain

Revolution Medicines has already been awarded a Commissioner's National Priority Voucher by the FDA, a designation that will accelerate the regulatory review timeline once a New Drug Application is submitted. The company has indicated it intends to file with the FDA and other global regulatory authorities based on the RASolute 302 data. The drug also holds Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic PDAC with G12 mutations, designations that reflect the FDA's recognition of the drug's potential to address a serious unmet need.

Three additional Phase 3 trials are underway, including two in earlier lines of pancreatic cancer treatment and one in non-small cell lung cancer, where KRAS mutations are also prevalent. The commercial opportunity in pancreatic cancer alone has been estimated by some analysts at more than ten billion dollars, a figure that reflects both the size of the patient population and the absence of any effective targeted therapy in the space until now.

What the RASolute 302 data do not yet establish is whether the survival benefit will translate into long-term durable responses for a meaningful subset of patients, or whether resistance will emerge on a timeline that limits the drug's practical impact. Pancreatic cancer has a long history of generating impressive early signals that do not sustain. The biology of RAS-driven tumors is complex, and the downstream signaling networks that RAS activates have multiple redundant pathways that can compensate when the primary driver is inhibited. Whether daraxonrasib's broad RAS(ON) inhibition is sufficient to prevent adaptive resistance, or whether combination strategies will ultimately be required, is a question that the ongoing trials and post-approval experience will need to answer.

A Moment Worth Marking

The standing ovation in Chicago was not for a drug that has cured pancreatic cancer. It was for a drug that has, for the first time, demonstrated that the biology of this disease can be meaningfully interrupted by a targeted agent in a large, randomized trial. That is a different kind of milestone, but it is a real one. The KRAS protein that has driven pancreatic cancer for decades while resisting every pharmacological attempt to silence it has now been credibly targeted. The question the field will spend the next several years answering is how far that targeting can go, and for how many patients it can translate into something that looks less like a statistical improvement and more like a genuine second chance.